资金来源对随机对照试验效应量的影响:2013-2015年横断面调查与Meta分析
该研究纳入2013至2015年发表于《柳叶刀》《新英格兰医学杂志》和《美国医学会杂志》的509项平行组随机对照试验,按资金来源分为营利性、混合和非营利性,采用随机效应模型Meta分析计算有利结局的汇总OR。结果显示营利性资金试验的OR为1.92(95%CI 1.72-2.14),高于混合资金(OR 1.34,95%CI 1.25-1.43)和非营利资金(OR 1.32,95%CI 1.26-1.39);作者认为该差异主要与营利性资金药物试验使用替代终点有关。
要点
- 营利性资金RCT有利结局OR为1.92(95%CI 1.72-2.14),高于混合资金OR 1.34(95%CI 1.25-1.43)和非营利资金OR 1.32(95%CI 1.26-1.39)。
- 营利性资金试验中临床终点和替代终点的有利结局OR均高于其他资金来源的RCT。
- 排除药物试验后,营利性资金RCT有利结局的OR降低;营利性资金药物试验的有利替代终点OR高于非营利资金试验。
核心结论
- 营利性资金RCT的有利结局OR高于非营利性和混合资金来源RCT,该差异主要与营利性资金药物试验使用替代终点有关。
研究设计与样本
- 横断面调查与Meta分析,纳入2013至2015年发表于《柳叶刀》《新英格兰医学杂志》和《美国医学会杂志》的509项平行组RCT,纳入标准为具有二分类主要终点。
- 按资金来源分为营利性、混合和非营利性,采用随机效应模型Meta分析计算汇总OR,并进行预设的敏感性、亚组和Meta回归分析。
主要发现
- 营利性资金RCT有利结局OR为1.92(95%CI 1.72-2.14),高于混合资金RCT的OR 1.34(95%CI 1.25-1.43)和非营利资金RCT的OR 1.32(95%CI 1.26-1.39)。
- 营利性资金试验中临床终点和替代终点的有利结局OR均高于其他资金来源的RCT。
- 排除药物试验后,营利性资金RCT有利结局的OR降低。
- 营利性资金药物试验的有利替代终点OR高于非营利资金试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trials financed by for-profit organizations have been associated with favorable outcomes of new treatments, although the effect size of funding source impact on outcome is unknown. The aim of this study was to estimate the effect size for a favorable outcome in randomized controlled trials (RCTs), stratified by funding source, that have been published in general medical journals. METHODS: Parallel-group RCTs published in The Lancet, New England Journal of Medicine, and JAMA between 2013 and 2015 were identified. RCTs with binary primary endpoints were included. The primary outcome was the OR of patients' having a favorable outcome in the intervention group compared with the control group. The OR of a favorable outcome in each trial was calculated by the number of positive events that occurred in the intervention and control groups. A meta-analytic technique with random effects model was used to calculate summary OR. Data were stratified by funding source as for-profit, mixed, and nonprofit. Prespecified sensitivity, subgroup, and metaregression analyses were performed. RESULTS: Five hundred nine trials were included. The OR for a favorable outcome in for-profit-funded RCTs was 1.92 (95% CI 1.72-2.14), which was higher than mixed source-funded RCTs (OR 1.34, 95% CI 1.25-1.43) and nonprofit-funded RCTs (OR 1.32, 95% CI 1.26-1.39). The OR for a favorable outcome was higher for both clinical and surrogate endpoints in for-profit-funded trials than in RCTs with other funding sources. Excluding drug trials lowered the OR for a favorable outcome in for-profit-funded RCTs. The OR for a favorable surrogate outcome in drug trials was higher in for-profit-funded trials than in nonprofit-funded trials. CONCLUSIONS: For-profit-funded RCTs have a higher OR for a favorable outcome than nonprofit- and mixed source-funded RCTs. This difference is associated mainly with the use of surrogate endpoints in for-profit-financed drug trials.
引用
- Falk Delgado A, Falk Delgado A. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis. Trials. 2017. PMID: 28292317. doi:10.1186/s13063-017-1872-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。